Lexicon Pharmaceuticals
LXRX
108 hedge funds and large institutions have $214M invested in Lexicon Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 23 reducing their positions, and 24 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 23
63% more call options, than puts
Call options by funds: $258K | Put options by funds: $158K
2.22% more ownership
Funds ownership: 97.99% → 100.21% (+2.2%)
5% more capital invested
Capital invested by funds: $204M → $214M (+$9.52M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 113 → 108 (-5)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.64M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.94M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.58M |
| 4 |
Lazard Asset Management
New York
|
+$1.48M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.55M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.41M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$801K |
| 4 |
HW
Hancock Whitney
Gulfport,
Mississippi
|
-$479K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$467K |
LXRX Hedge Fund Activity: Q2 2020 in Review
108 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2020, worth a combined $214M — up 4.7% from $204M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of LXRX and 19 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 38 added.
The largest buyer was Morgan Stanley, adding an estimated $3.64M. The largest seller was Fidelity Investments, cutting an estimated $2.55M.
- 108 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2020, down from 113 in Q1 2020.
- Funds reported $214M of Lexicon Pharmaceuticals stock for Q2 2020, up 4.7% quarter-over-quarter.
- 19 funds opened new Lexicon Pharmaceuticals positions in Q2 2020 and 24 closed out, a net change of -5 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2020 was Morgan Stanley, an estimated $3.64M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2020 was Fidelity Investments, an estimated $2.55M sold.
Based on aggregated 13F filings for Q2 2020.